Background: Cardiovascular disease remains the most common cause of death in industrialized countries. The use of betablockers is well established as a secondary prevention of myocardial infarction. However, little is known about the benefits of beta-blockers for people living with dementia. Objective: To evaluate the use of beta-blockers in people with dementia who have had a myocardial infarction, in order to identify associations between medication use, mortality, re-infarction and functional decline.
INTRODUCTION
Cardiovascular disease remains the most common cause of death in industrialized countries [1] . Advances in both primary and secondary prevention of myocardial infarction (MI) have had a significant positive impact on reducing morbidity and mortality from cardiovascular disease. Beta-blockers are well-established for pharmacological secondary prevention [2] , and have been found to reduce mortality when used in post MI in the general population [3, 4] .
The evidence for the use of beta-blockers is predominantly drawn from clinical trials excluding persons living with dementia [5] . This is despite the fact that cardiovascular disease and dementia commonly co-exist. A 2017 estimate found 850,000 people in the UK living with dementia [6] with concomitant diagnoses of ischemic heart disease found in almost a quarter of people with dementia [7] . In prior analyses of approximately 12,000 individuals in the UK's General Practice Research Database, prescriptions of beta-blockers were found in almost 20% of persons with Alzheimer's disease or vascular dementia, with highest levels found in the latter group [8] .
In a population living with dementia, any potential benefit from pharmacotherapy must be offset by potential risks. Persons living with dementia have higher rates of hospitalization, shorter life expectancy [9] , and are often on multiple medications [10] , where concordance can be difficult, polypharmacy is costly and side-effects and drug interactions unknown. Such adverse outcomes may be undetected in the context of a clinical trial [11] . Furthermore, life expectancy of those with dementia may be too short to yield benefit from pharmacological secondary prevention. Polypharmacy is also associated with reduced physical and cognitive function [12] and the complexity of medication regimens has been linked to functional impairment due to medication administration errors [10] , themselves more common in those with cognitive impairment [9] . Given these issues, existing randomized controlled trials are limited in their generalizability for persons living with dementia.
In order to address the question of whether betablockers might continue to be beneficial in persons living with dementia, we performed a systematic review to assess the quantity and quality of evidence supporting beta-blocker therapy as pharmacological secondary prevention for persons living with dementia.
METHODS

Objectives
We set out to answer the following question: is there any evidence to support the role of beta-blockers in the secondary prevention of MI in individuals with established dementia? A secondary objective involved identifying the risks and benefits of betablocker use in this population. We searched for all types of study design, that is, both randomized controlled trials and observational studies.
Inclusion criteria Population
Peer-reviewed studies published since 1965 (when beta-blockers were first used in the secondary preven-tion of MI [13] ) that included persons with previous MI (including STEMI and NSTEMI) and also reporting of any associations in individuals with a diagnosis of dementia/cognitive impairment.
Intervention
Both interventional and observational studies investigating beta-blocker use.
Outcomes
Studies reporting mortality/survival, re-infarction rates, functional decline, and/or serious adverse events related to medication use.
Analysis
Any quantification of associations between these outcomes and beta-blocker use.
Exclusion criteria
We excluded any non-English language articles
Search strategy
We identified publications by first developing search terms through an exploratory Medline search, recording relevant keywords found in the title, abstract, and Medical Subject Heading (MeSH) terms. This informed a comprehensive search using the relevant keywords and synonyms on Medline, Embase, and ISI Web of Science databases (Supplementary Material). Keywords used were 'beta', 'ischaemic heart disease', and 'dementia', along with synonyms and variants. A comprehensive list of prescribed beta-blockers was obtained from the British National Formulary and were included in the search. No filters were used, searching from 1965 up to October 20, 2018. We did not identify any existing protocols through our search or registered on PROSPERO. No de-duplication was performed, and all abstracts were independently reviewed by two reviewers (DL, SA) with disagreements resolved by consensus. Full texts were considered further and data extracted from included studies using a pro forma.
Data abstraction and validity assessment
For each of the studies meeting the inclusion criteria, we extracted data of interest including: age, sex, total number of participants, number who had cognitive impairment, and number of study participants on beta-blockers. We used the Newcastle-Ottawa assessment scale to assess risk of bias and evaluate study quality ( Supplementary Table 1 ) [14] . The principal summary measures of interest were recorded as odds ratios, risk ratios, and hazard ratios. We did not identify studies of sufficient similarity to undertake a meta-analysis.
RESULTS
The initial search provided 230 abstracts from Pubmed, 363 from Embase, and 118 from ISI Web of Science ( Fig. 1) .
We identified twenty-one articles that met inclusion criteria and merited full-text review ( Table 1) . After applying exclusion criteria, only two directly quantified beta-blocker use in relation to our outcomes of interest in individuals with dementia [15, 16] . The first study investigated dementia status (as documented in hospital notes) in relation to outcomes in Medicare beneficiaries admitted to hospital with an acute MI between 1994-1995 (Medicare study). The second study included US nursing home residents post-acute MI examining associations between beta-blockers and functional, mortality, and rehospitalization outcomes between 2007-2010 (Nursing Home study). This study grouped patients by their score on the Cognitive Performance Scale as having either normal cognition, mild-moderate dementia, or moderately severe-very severe dementia. Both were secondary analyses of electronic health records. Mortality was the primary outcome measure in both studies. The characteristics of both studies are detailed in Table 2 . The two studies received a Newcastle-Ottawa scoring of 7 and 8 with a maximum obtainable score of 9 indicating 'fair' to 'good' study design and methodology.
Mortality
The Medicare study described an increase in mortality of individuals with dementia at 30 days (RR = 1.16; 95%CI, 1.09-1.22) and one year follow were less likely to be on beta-blockers when compared to participants without dementia; though no direct effect size was calculated for the effect of beta-blocker use on mortality in either of these subgroups. However, concurrent lower ACE inhibitor use and fewer cardiac interventions (thrombolysis, catheterization, coronary angioplasty) in those with dementia raise the possibility these factors, either in isolation or in combination with beta-blocker underuse account for the observed higher mortality, rather than beta-blocker use alone. The Nursing Home study showed the use of beta-blockers to reduce mortality (HR = 0.74; 95%CI, 0.67-0.83) in the cohort as a whole, but also in the subgroup with moderate/severe cognitive impairment (HR = 0.74; 95%CI, 0.64-0.86). For the study population as a whole, the reported number needed to treat was 26 (95% CI, .
Reinfarction rates and cardiovascular morbidity
No evidence was available from either study on the association of beta-blockers on the rate of subsequent myocardial infarction or consequent cardiovascular morbidity in persons living with dementia.
Negative sequelae: Hospital readmission, adverse drug reactions, and functional decline
The Nursing Home study reported that betablockers were not associated with increase in readmission from a nursing home, irrespective of dementia status (OR 1.06; 95%CI, 0.98-1.14). The same study also showed more functional decline in individuals with moderate to severe cognitive impairment who were also on a beta-blocker (OR 1.34; 95%CI, 1.11-1.61)), where functional decline was defined as a loss of 3 points on the Morris Scale of Independence in Activities of Daily Living (ADLs) [17] in the first three months post-hospital discharge. This relates to a number-needed-to-harm as 36 (95%CI, . This functional decline was not seen in individuals with intact cognition or mild dementia (OR 1.03; 95%CI, 0.89-1.20). No negative sequelae were described in the Medicare study, and neither study specifically reported rates of adverse drug reaction.
DISCUSSION
In two studies of 10,992 individuals in a nursing home setting and 129,092 Medicare recipients, we found weak evidence of beta-blockers being associated with lower mortality in individuals with dementia. However, associations between betablocker use and worse functional outcomes in persons living with moderately-severe or worse dementia were also evident. Taken together, our findings suggest that despite the widespread practice of betablocker prescription for secondary prevention in persons living with dementia, there is minimal evidence to support any benefit, and potential evidence of harm.
The findings from our systematic review should be interpreted with caution given the paucity of evidence identified. Included studies were observational cohorts, rather than randomized trials. Neither reported follow-up data beyond 12 months, when beta-blockers may have mortality benefit, at least in non-cognitively impaired populations [18] . In addition, neither paper reported re-infarction rates, reduction of which is a key benefit of beta-blocker use in younger populations [19] . Another limitation is that the dementia diagnoses in both studies relied on administrative data, which is likely to under-ascertain cases. Any resultant misclassification bias might then obscure true effects of beta-blockers in this group.
Use of beta-blockers as secondary prevention of MI in the general population dates back to the 1960 s [5] . In 1999, the best contemporary meta-analysis on beta-blockers and all-cause mortality noted an overall annual survival benefit, but no evidence after 1982 that beta-blockers directly led to differences in mortality [5] . With effective angioplasty and catheter revascularization now routine within 24 hours of MI [20, 21] , the attributable fraction from beta-blockers on secondary outcomes may have decreased over time. How such trends may differentially affect older people with or without dementia has yet to be established. Indeed, the finding of associations between beta-blockers and high rates of functional decline in the Nursing Home paper may be an example of this. Beta-blocker use may reduce mortality in this group and prolong the lives of individuals who are likely to experience severe functional decline due to their dementia. Equally, this group may be more prone to side effects from beta-blocker use and experience more frequent falls or hypotensive episodes that in turn lead to physical and functional deconditioning.
We highlight the paucity of evidence on betablocker use in persons living with dementia. Further studies might include randomized trials, all of which should incorporate a range of outcome measures beyond mortality (secondary cardiac events, functional status, frailty, quality of life). Moreover, there is need to account for people living with dementia at all severities and settings as those with mild dementia living independently may have little in common with more advanced disease in institutional care. At best, beta-blocker use should be considered on a patient by patient basis with explanation to the patient and any carers of a possible mortality benefit, balanced against the possible harm to the functional status. This could result in a reduced quality of extended life. This would be explained with a view to patient and family empowerment in decision making around stopping versus continuing therapy.
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